The present disclosure provides systems and methods for disrupting neuronal oscillations. A neurostimulation system includes a stimulation lead comprising at least one contact, and an implantable pulse generator (IPG) communicatively coupled to the stimulation lead and configured to cause stimulation to be applied to a patient using no more than two contacts of the stimulation lead by causing a first burst of stimulation to be delivered, and causing a second burst of stimulation to be delivered within a neuronal refractory period that follows the first burst of stimulation.

Devices for controlling spinal cord modulation for inhibiting pain, and associated systems and methods, including controllers for automated parameter selection are disclosed. A particular embodiment includes receiving a first input corresponding to a location of a signal delivery device implanted in a patient, establishing a positional relationship between the signal delivery device and an anatomical feature of the patient, receiving a second input corresponding to a medical indication of the patient, and, based at least in part on the positional relationship and the indication, automatically identifying a signal delivery parameter in accordance with which a pulsed electrical signal is delivered to the patient via the signal delivery device.

An extravascular or intravascular neural interface is disclosed containing electrodes for neurostimulation of the vessel. The devices are housed in flexible substrates formed from a multilumen tubing housing conductors for electrodes positioned in a distal serpentine shaped end of the device. The distal serpentine shaped end includes rows or strips of electrodes or coil electrodes.

Embodiments are directed to an implantable medical device comprising therapeutic stimulation circuitry for controlling delivery of a medical therapy to a patient, the therapeutic stimulation circuitry having at least one lead having electrodes for delivering the medical therapy, The implantable medical device further comprises measurement circuitry for determining characteristics of the at least one lead, a processor for controlling the IMD according to executable code, and memory for storing data and executable code, wherein the executable code comprises instructions for causing the processor to receive a plurality of voltage measurements associated with the electrodes, and calculate values for an impedance model of the electrode/tissue interface.

An electrical stimulation device includes an electrical stimulation signal generating circuit. The electrical stimulation signal generating circuit has a first channel for providing a first electrical stimulation signal and a second channel for providing a second electrical-stimulation signal. A time difference exists between the first electrical-stimulation signal provided by the first channel and the second

An example of a system includes a blood pressure modulation device and a controller. The blood pressure modulation device may be configured to deliver a therapy to chronically maintain blood pressure within a prescribed range. The blood pressure modulation device may include a neuromodulator configured to deliver neuromodulation energy to neural tissue in a spinal cord or near the spinal cord using a first parameter set. The controller may include analyzer circuitry configured to determine an actual or anticipated blood pressure demand event indicated for a blood pressure change, and therapy parameter adjuster circuitry configured to respond to the actual or anticipated blood pressure demand event by delivering neuromodulation energy using a second parameter set to change the blood pressure.

The disclosure concerns a method for the treatment of cervical dystonia, comprising inserting a stimulation device into the brain of a patient, the stimulation device being configured to provide electrical stimulation to affect first and second stimulation targets within the brain. The first stimulation target is the subthalamic nucleus (STN); and the second stimulation target is the ventral intermediate nucleus (VIM), or the ventralis oralis posterior thalamus (VOP), or both the ventral intermediate nucleus (VIM) and the ventralis oralis posterior thalamus (VOP).

An implantable medical device is configured to receive an input that specifies a time domain allocation between two or more stored stimulation programs and to provide control signals corresponding to each of the two or more stimulation programs to stimulation circuitry to interleave the two or more stimulation programs in time according to the input. The time domain allocation may set a proportion of time during which each of the stimulation programs is active during repeating epochs. The time domain allocation may be set by a user to transition between configured stimulation programs or to specify stimulation that is based on two or more different stimulation programs. The time domain allocation may also be adjusted automatically to optimize an indication of an effectiveness of stimulation that is provided by the patient.

An implantable neurostimulator has an implantable electrode array comprising a plurality of stimulus electrodes. Each stimulus electrode is configured to deliver electrical stimuli to neural tissue. An implantable control module is configured to produce the electrical stimuli delivered by the stimulus electrodes, and is configured to effect current steering. The control module has a plurality of related current sources, each current source configured to deliver a respective stimulus current which is defined in a first part by a shared current control signal which is shared by each of the related current sources, and which is defined in a second part by a respective unique current control signal which is not shared by all of the related current sources.

Methods for automatically programming a signal generator in a patient therapy system and associated systems are disclosed. A representative method comprises retrieving data including therapy program parameters, level of efficacy, and medication use corresponding to a plurality of time periods; identifying from the data a target time period having a corresponding level of efficacy; determining from the data if medication was used during the target time period; determining from the data if medication was used during a prior time period immediately before the target time period; calculating a lead position confidence factor; and programming the signal generator to repeat therapy with the therapy program parameters corresponding to the target time period if the confidence factor is greater than a threshold value and medication was used during the prior time period and not during the target time period.